Skip to main content
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Main navigation - Mobile
Coherus plots 33% biosim discount to battle Amgen’s Neulasta
Friday, November 9, 2018
Coherus dialed up pressure on Amgen with its new Neulasta biosimilar approval, and now the company has unveiled its plan to steal market share.
Coherus' Neulasta biosim nod steps up pressure on Amgen
Monday, November 5, 2018
Coherus won an FDA nod for its biosimilar to Amgen's Neulasta, heating up the market share fight—and touching off predictions of price competition.
Mylan biosim ready to challenge Amgen blockbuster Neulasta
Tuesday, June 5, 2018
Amgen's $3.9 billion Neulasta, one of the biggest drug targets for biosim developers, is finally slated to face competition after a 2015 patent loss.
AbbVie's Humira wins another biosim reprieve with Biogen deal
Thursday, April 5, 2018
AbbVie shielded Humira from another U.S. biosims threat in a deal that makes it "increasingly unlikely" any copycats will launch here before 2023.
With Amgen biosim deal, AbbVie wins 5-year Humira reprieve
Thursday, September 28, 2017
AbbVie and Amgen entered a patent settlement that will hold off Amgen's Humira biosimilar in the U.S. until 2023.
AbbVie executives may back off price-hike vow: report
Monday, September 25, 2017
AbbVie is thinking about reneging on its 10% price-hike limit announced in January, executives said in a recent meeting with analysts.
With $39B in cash, could Amgen use a deal?
Wednesday, July 26, 2017
Amgen beat revenue expectations in second-quarter earnings released Tuesday, but some analysts think the company needs M&A. Its executives? Not so much.
Key Humira patent goes down, but copycats shouldn't celebrate yet
Wednesday, May 17, 2017
One of AbbVie’s Humira patents bit the dust late Tuesday, marking a win for copycats. But they still have a long way to go before they’ll really be able to celebrate.
Amgen sues biosim maker for stealing Neulasta secrets
Tuesday, March 7, 2017
Awaiting its chance to launch a biosimilar of Amgen’s blockbuster Neulasta, Coherus now faces a lawsuit alleging it poached its rival's employees to steal trade secrets.